Skip to main content
Equibles
ORGO logo

ORGO · Organogenesis Holdings Inc. · Metrics

Track ORGO — free

Use ORGO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ORGO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.99 -0.03 (-2.81%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Market Cap
$131.25M
Shares
128.67M
Volume · Oct 21 1.15M Avg daily vol (3M) 793.13K

ORGO metrics

93 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.99
Market cap
$131.25M

Price action

20 metrics
Price change (1W)
-15.7%
Price change (30D)
-27.1%
Price change (3M)
-61.9%
Price change (6M)
-57.7%
Price change (YTD)
-80.3%
Price change (1Y)
-75.0%
Trailing year
Price change (5Y)
-90.8%
52-week high
$6.54
52-week low
$1.00
Change from 52-week high
-84.4%
Change from 52-week low
+2.0%
Annualized volatility
77.9%
Annualized volatility (3M)
68.5%
Beta
1.3
RSI (14D)
22.2
Price vs SMA 50
-31.9%
Price vs SMA 200
-59.3%
Avg volume (3M)
783,481
Relative volume
2.4
Average dollar volume
$1.32M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
128.67M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 348.5%
P / book
0.9
reciprocal yield 113.0%
FCF yield
15.9%
TTM · current market cap
Buyback yield
—
P / FCF
6.3
reciprocal yield 15.9%
P / operating cash flow
4.1
reciprocal yield 24.4%
Earnings yield
-64.1%

Historical valuation

8 metrics
P / E historical average (3Y)
38.7×
reciprocal yield 2.6%
P / E historical average (5Y)
27.9×
reciprocal yield 3.6%
EV / revenue historical average (3Y)
0.9×
reciprocal yield 111.0%
EV / revenue historical average (5Y)
1.8×
reciprocal yield 54.5%
EV / EBIT historical average (3Y)
19.5×
reciprocal yield 5.1%
EV / EBIT historical average (5Y)
30.9×
reciprocal yield 3.2%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-7.8%
Trailing 12 months
Net margin
-18.4%
Gross profit (TTM)
$347.99M
Operating profit (TTM)
−$35.87M
Net income (TTM)
−$84.16M
Trailing 12 months
Diluted EPS (TTM)
$-0.79
FCF margin
4.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$3.43
Gross profit per diluted share (TTM)
$2.67
Operating profit per diluted share (TTM)
$-0.31
EBITDA per diluted share (TTM)
$-0.19
Net income per diluted share (TTM)
$-0.68
Operating cash flow per diluted share (TTM)
$0.23
Free cash flow per diluted share (TTM)
$0.15
Capital expenditures per diluted share (TTM)
$0.08
R&D per diluted share (TTM)
$0.44
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$2.36

Growth

11 metrics
Revenue growth YoY
-56.7%
Year over year
Net income growth YoY
+4,201.0%
Revenue (TTM)
$457.45M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.4%
Year over year · more shares
Revenue CAGR (3Y)
+7.8%
Revenue CAGR (5Y)
+10.8%
EPS CAGR (3Y)
+7.7%
EPS CAGR (5Y)
+0.0%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-56.8%
Return on assets
-20.7%
Debt / equity
—
Current ratio
3.5
EBITDA (TTM)
−$19.93M
Free cash flow (TTM)
$20.84M
Quick ratio
3.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$46.10M
Total assets
$406.45M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$31.97M
Capital expenditures (TTM)
$11.13M
R&D (TTM)
$56.97M
SG&A (TTM)
$299.07M
Stock compensation (TTM)
$14.08M
R&D / revenue
12.5%
Stock compensation / revenue
3.1%

Ownership (13F)

9 metrics
13F filers
135
13F filer change QoQ
+14
Institutional ownership
51.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
20.1%
Private-fund adviser ownership
8.3%
Active holders' share change QoQ
+2.8%
Holder tenure
17.6
Price vs estimated holder cost
-38.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.3%

Short interest

3 metrics
Short interest
11.7%
Latest settlement · 26.6 days to cover
Days to cover
26.6d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1661181 CUSIP 68621F102 13F (30d) 15 filings 15 filers Visit website Investor relations